Glaucoma is the second most common cause of world blindness (following cataract) with
estimated cases reaching 79.6 million by 2020. Although the etiology of glaucoma is multi …

The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and
the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence …

Purpose To evaluate the concentrations of brimonidine and timolol in the vitreous and
aqueous humors after instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed …

Purpose: To evaluate the concentrations of brimonidine and brinzolamide in the vitreous
and aqueous humor after instillation of a 0.1% brimonidine tartrate and 1% brinzolamide …

Purpose: To investigate the effect of fixed combination versus concomitant unfixed topical
glaucoma treatment on patients' adherence and ocular surface health. Patients and …

Aim The aim of this study is to compare the 24-hour efficacy of dorzolamide/timolol-fixed
combination (DTFC) and brimonidine/timolol-fixed combination (BTFC) in primary open …

Introduction This multicenter, randomized, comparative, and investigator-masked crossover
clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1 …

Introduction Fixed-combination glaucoma medications have altered the paradigm of ocular
hypertension and glaucoma treatment and are in widespread use today. A comprehensive …

Introduction: The only evidence-based mechanism for prevention and treatment of
glaucomatous optic neuropathy is decreasing the intraocular pressure (IOP). Prescribing …

Glaucoma is a collection of diseases characterized by multifactorial progressive changes
leading to visual field loss and optic neuropathy most frequently due to elevated intraocular …